CMMB Share Price Performance
Recent CMMB News & Updates
No updates
Chemomab Therapeutics Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.70
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Chemomab Therapeutics Ltd. Competitors
About CMMB
- Founded
- 2011
- Employees
- n/a
- CEO
- WebsiteView website
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Israeli Market Performance
- 7 Days: -1.5%
- 3 Months: 21.3%
- 1 Year: 66.8%
- Year to Date: 28.8%
Over the last 7 days, the market has dropped 1.5%, driven by a loss of 1.9% in the Financials sector. In the last year, the market is actually up 67%. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading